| 20.97 -0.31 (-1.46%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 42.14 |
1-year : | 53.51 |
| Resists | First : | 36.08 |
Second : | 45.81 |
| Pivot price | 25.95 |
|||
| Supports | First : | 20.32 |
Second : | 16.91 |
| MAs | MA(5) : | 21.84 |
MA(20) : | 30.49 |
| MA(100) : | 38.84 |
MA(250) : | 30.73 |
|
| MACD | MACD : | -6  |
Signal : | -5.6 |
| %K %D | K(14,3) : | 2.5 |
D(3) : | 3.5 |
| RSI | RSI(14): 16 |
|||
| 52-week | High : | 71.5 | Low : | 8.72 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ QURE ] has closed above bottom band by 30.4%. Bollinger Bands are 75.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 21.77 - 21.95 | 21.95 - 22.07 |
| Low: | 19.98 - 20.16 | 20.16 - 20.29 |
| Close: | 20.71 - 21.01 | 21.01 - 21.21 |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Thu, 15 Oct 2026
UBS sets USD 48 target for uniQure stock as it trades 1.60 percent lower - ad-hoc-news.de
Tue, 13 Oct 2026
QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure - Stocktwits
Fri, 09 Oct 2026
QURE Stock Just Shot Up 8% - uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
Thu, 08 Oct 2026
uniQure N.V. (QURE) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore
Tue, 06 Oct 2026
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop - Business Wire
Tue, 06 Oct 2026
uniQure N.V. (QURE) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 97.7 (%) |
| Shares Short | 8,720 (K) |
| Shares Short P.Month | 9,870 (K) |
| EPS | -4.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.67 |
| Profit Margin | 0 % |
| Operating Margin | -872.3 % |
| Return on Assets (ttm) | -15.8 % |
| Return on Equity (ttm) | -157.7 % |
| Qtrly Rev. Growth | 11 % |
| Gross Profit (p.s.) | -1.66 |
| Sales Per Share | 0.26 |
| EBITDA (p.s.) | -2.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -161 (M) |
| Levered Free Cash Flow | -78 (M) |
| PE Ratio | -5.21 |
| PEG Ratio | 0 |
| Price to Book value | 4.48 |
| Price to Sales | 77.87 |
| Price to Cash Flow | -9.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|